pharmacogenomics-cbs-psp

📖 Wiki Page

therapeutic2053 wordssynced 2026-04-02

Precision Pharmacogenomics for CBS/PSP

...

Precision Pharmacogenomics for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">pharmacogenomics-cbs-psp</th>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Chromosome</td>
</tr>
<tr>
<td class="label">CYP2D6</td>
<td>22q13.2</td>
</tr>
<tr>
<td class="label">CYP3A4</td>
<td>7q21.1</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>CBS/PSP Relevance</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Strong PSP risk factor (H1 haplotype)</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Risk factor for CBS/PSP with potential synucleinopathy overlap</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>Modulates neurodegeneration and lipid metabolism</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Activity Score</td>
</tr>
<tr>
<td class="label">Poor Metabolizer (PM)</td>
<td>0</td>
</tr>
<tr>
<td class="label">Intermediate Metabolizer (IM)</td>
<td>0.5-1.0</td>
</tr>
<tr>
<td class="label">Normal Metabolizer (NM)</td>
<td>1.5-2.5</td>
</tr>
<tr>
<td class="label">Ultra-rapid Metabolizer (UM)</td>
<td>>2.5</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>Function</td>
</tr>
<tr>
<td class="label">*1 (wild-type)</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">*2</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">*3</td>
<td>Null</td>
</tr>
<tr>
<td class="label">*4</td>
<td>Null</td>
</tr>
<tr>
<td class="label">*5</td>
<td>Null</td>
</tr>
<tr>
<td class="label">*10</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">*17</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">*41</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Allele Frequency</td>
</tr>
<tr>
<td class="label">*22</td>
<td>~5-10%</td>
</tr>
<tr>
<td class="label">*1B</td>
<td>~2-5%</td>
</tr>
<tr>
<td class="label">2 to 27</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Service</td>
<td>Testing Method</td>
</tr>
<tr>
<td class="label">Genomind</td>
<td>Microarray/Sequencing</td>
</tr>
<tr>
<td class="label">OneOme</td>
<td>NGS-based</td>
</tr>
<tr>
<td class="label">Mayo Clinic Pharmacogenomics</td>
<td>Clinical-grade PCR</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>H1 Haplotype</td>
</tr>
<tr>
<td class="label">Population Frequency</td>
<td>~75% (European)</td>
</tr>
<tr>
<td class="label">4R Tau Expression</td>
<td>Upregulated</td>
</tr>
<tr>
<td class="label">CBS/PSP Risk</td>
<td>Strongly increased</td>
</tr>
<tr>
<td class="label">Subhaplotypes</td>
<td>H1a, H1b, H1c, H1P</td>
</tr>
<tr>
<td class="label">Haplotype</td>
<td>Anti-tau Therapy Consideration</td>
</tr>
<tr>
<td class="label">H1/H1</td>
<td>Monitor closely; potential for stronger response</td>
</tr>
<tr>
<td class="label">H1/H2</td>
<td>Intermediate profile</td>
</tr>
<tr>
<td class="label">H2/H2</td>
<td>May require higher doses</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Function</td>
</tr>
<tr>
<td class="label">N370S</td>
<td>Mildly reduced activity</td>
</tr>
<tr>
<td class="label">L444P</td>
<td>Significantly reduced activity</td>
</tr>
<tr>
<td class="label">E326K</td>
<td>Mildly reduced activity</td>
</tr>
<tr>
<td class="label">RecNCI</td>
<td>Severely reduced activity</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>Effect on AD Risk</td>
</tr>
<tr>
<td class="label">ε2</td>
<td>Protective</td>
</tr>
<tr>
<td class="label">ε3 (reference)</td>
<td>Neutral</td>
</tr>
<tr>
<td class="label">ε4</td>
<td>Risk (dose-dependent)</td>
</tr>
<tr>
<td class="label">APOE Genotype</td>
<td>Lipid Therapy Response</td>
</tr>
<tr>
<td class="label">ε2/ε2 or ε2/ε3</td>
<td>Enhanced response</td>
</tr>
<tr>
<td class="label">ε3/ε3</td>
<td>Normal response</td>
</tr>
<tr>
<td class="label">ε3/ε4 or ε4/ε4</td>
<td>Reduced response</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Metabolism</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>COMT, DDC</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>MAO-B, CYP3A4</td>
</tr>
<tr>
<td class="label">Selegiline</td>
<td>CYP2D6, CYP3A4</td>
</tr>
<tr>
<td class="label">Entacapone</td>
<td>COMT</td>
</tr>
<tr>
<td class="label">Amantadine</td>
<td>Renal excretion</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Metabolism</td>
</tr>
<tr>
<td class="label">Sertraline</td>
<td>CYP2C19, CYP2D6</td>
</tr>
<tr>
<td class="label">Escitalopram</td>
<td>CYP2C19, CYP3A4</td>
</tr>
<tr>
<td class="label">Venlafaxine</td>
<td>CYP2D6</td>
</tr>
<tr>
<td class="label">Duloxetine</td>
<td>CYP1A2, CYP2D6</td>
</tr>
<tr>
<td class="label">Bupropion</td>
<td>CYP2B6</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Metabolism</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>CYP2D6, CYP3A4</td>
</tr>
<tr>
<td class="label">Rivastigmine</td>
<td>Non-CYP</td>
</tr>
<tr>
<td class="label">Galantamine</td>
<td>CYP2D6, CYP3A4</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Renal</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Metabolism</td>
</tr>
<tr>
<td class="label">Quetiapine</td>
<td>CYP3A4</td>
</tr>
<tr>
<td class="label">Lorazepam</td>
<td>Glucuronidation</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>CYP3A4</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>CYP1A2</td>
</tr>
<tr>
<td class="label">Metabolizer Type</td>
<td>CYP2D6 Substrates</td>
</tr>
<tr>
<td class="label">Poor Metabolizer</td>
<td>Reduce 50-75%</td>
</tr>
<tr>
<td class="label">Intermediate</td>
<td>Reduce 25%</td>
</tr>
<tr>
<td class="label">Normal</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Ultra-rapid</td>
<td>Consider increase 50%</td>
</tr>
<tr>
<td class="label">Comorbidity</td>
<td>Gene-Drug Concern</td>
</tr>
<tr>
<td class="label">Cardiovascular disease</td>
<td>Warfarin, clopidogrel</td>
</tr>
<tr>
<td class="label">Diabetes</td>
<td>Metformin</td>
</tr>
<tr>
<td class="label">Renal impairment</td>
<td>Most drugs</td>
</tr>
</table>

Overview

Precision pharmacogenomics offers a transformative approach to treating Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) by tailoring medication selection and dosing to an individual's genetic profile. This page provides a practical guide for clinicians and patients seeking to optimize therapeutic outcomes through genetic-informed prescribing.

The management of CBS and PSP presents unique pharmacological challenges:

Complex symptom profiles requiring multiple concurrent medications
Progressive disease necessitating ongoing treatment adjustments
Age-related changes in drug metabolism
Overlap with other neurodegenerative conditions (particularly Parkinson's disease)

Genetic variations in drug-metabolizing enzymes, drug targets, and disease-risk genes can significantly impact medication efficacy and tolerability. This guide synthesizes current evidence for pharmacogenomic applications in CBS/PSP care.

1. Key Pharmacogenomic Targets in CBS/PSP

1.1 Cytochrome P450 Enzymes

The CYP450 enzyme family is central to drug metabolism in movement disorders. Two enzymes are particularly relevant for CBS/PSP pharmacotherapy:

1.2 Disease-Risk Genes with Therapeutic Implications

2. CYP2D6 and CYP3A4 Variants

2.1 CYP2D6 Polymorphisms

CYP2D6 exhibits extensive genetic polymorphism, resulting in four primary metabolizer phenotypes[@cyp2d6_levodopa]:

Key CYP2D6 Alleles

2.2 CYP3A4 Polymorphisms

CYP3A4 genetic variation is less extensive than CYP2D6 but clinically significant[@cyp3a4_rasagiline]:

2.3 Clinical Impact on CBS/PSP Medications

Mermaid diagram (expand to render)

3. Pharmacogenomic Testing Services

3.1 Commercial Platforms

Three major commercial platforms offer comprehensive pharmacogenomic testing relevant to CBS/PSP:

3.2 Recommended Testing Strategy for CBS/PSP

Tier 1 — Essential Testing:

CYP2D6 (full allele panel including 1, 2, 3, 4, 5, 6, 10, 17, *41, gene duplication)
CYP3A4 (*22 allele if available)
COMT (Val158Met)

Tier 2 — Enhanced Testing (if available):

All Tier 1 plus: MAPT haplotype, GBA, APOE

3.3 Interpreting Results

Mermaid diagram (expand to render)

4. MAPT Haplotype and Therapeutic Response

4.1 Haplotype Overview

The MAPT gene exists in two major haplotypes defined by a 900 kb inversion at 17q21.31[@mapt_haplotype_therapy]:

4.2 Clinical Implications for Therapy

MAPT H1 Haplotype Effects:

Tau-targeted therapies: H1 carriers may show differential response to anti-tau immunotherapies
Lithium response: Preliminary evidence suggests H1 carriers may respond differently to lithium
Neuroinflammation: H1 haplotype associated with enhanced neuroinflammatory responses

4.3 Therapeutic Recommendations by Haplotype

5. GBA Variants in CBS/PSP

5.1 Clinical Significance

GBA (glucocerebrosidase) variants are increasingly recognized in CBS/PSP, with important implications[@gba_cbs_psp]:

5-10% of PSP cases carry GBA variants
Often indicates synucleinopathy overlap despite clinical CBS/PSP presentation
May affect response to ambroxol (GBA modulator under investigation)

5.2 Key GBA Variants

5.3 Pharmacogenomic Implications

GBA Variant Carriers:

May respond better to ambroxol (under investigation for CBS/PSP)
Consider synucleinopathy overlap in diagnosis
Monitor for Parkinson's disease development
GBA variants affect response to:

Mermaid diagram (expand to render)

6. APOE and Lipid-Based Therapies

6.1 APOE Polymorphisms

APOE has three common alleles affecting lipid metabolism and neurodegeneration[@apoe_lipid_therapy]:

6.2 Impact on CBS/PSP Therapeutics

Lipid-Based Therapies:

APOE ε4 carriers may show altered response to:
Omega-3 fatty acid supplements
Lecithin-based formulations
Statins (for comorbidities)

Immunotherapy Considerations:

APOE genotype may influence response to anti-tau immunotherapies
ε4 carriers may show different adverse event profiles

6.3 Dosing Recommendations by APOE

7. Drug-Gene Interaction Tables

7.1 Dopaminergic Medications

7.2 Antidepressants (Commonly Used in CBS/PSP)

7.3 Cognitive Enhancers

7.4 Medications for Psychiatric Symptoms

8. Personalized Dosing Algorithm

Mermaid diagram (expand to render)

8.1 Step-by-Step Dosing Protocol

Obtain pharmacogenomic testing before initiating high-risk medications

Determine metabolizer status for CYP2D6 and CYP3A4

Identify disease-risk genotypes (MAPT, GBA, APOE)

Apply genotype-guided dosing using the tables above

Establish monitoring plan based on medication and genotype

Reassess at each visit; consider repeat testing if new symptoms emerge

8.2 Dose Adjustment Quick Reference

9. Special Considerations

9.1 Geriatric Pharmacogenomics

Age-related changes interact with genetic variability:

Reduced hepatic blood flow: Complements CYP polymorphism effects
Decreased renal function: Affects drug elimination independent of metabolism
Polypharmacy: Increases drug-drug interaction potential

Recommendation: For patients >75 years with CYP polymorphisms, start at the lower end of recommended dose adjustments.

9.2 Comorbidity Considerations

9.3 Drug-Drug Interactions

CYP2D6 Inhibitors (avoid or adjust):

Fluoxetine, Paroxetine
Quinidine
Bupropion
Terbinafine

CYP3A4 Inducers (may reduce efficacy):

Rifampin
Carbamazepine
St. John's wort

10. Clinical Implementation

10.1 Practical Workflow

Pre-visit: Identify patients likely to benefit from testing

Testing: Order pharmacogenomic panel (one-time)

Interpretation: Use clinical decision support or pharmacist consultation

Prescribing: Apply genotype-guided dosing

Monitoring: Document response and adjust as needed

Follow-up: Reassess at each visit; update treatment plan

10.2 Resources for Clinicians

CPIC Guidelines: https://cpicpgx.org
PharmGKB: https://www.pharmgkb.org
DPWG (Dutch Pharmacogenetics Working Group): https://www.knmp.nl

11. Related Pages

[Section 160: Pharmacogenomics and Personalized Medicine in CBS/PSP](/therapeutics/section-160-pharmacogenomics-cbs-psp)
[Section 216: Advanced Pharmacogenomics for CBS/PSP](/therapeutics/section-216-pharmacogenomics-cbs-psp)
[CYP2D6 Gene Page](/genes/cyp2d6)
[CYP3A4 Gene Page](/genes/cyp3a4)
[MAPT Haplotypes](/genes/mapt-haplotypes)
[GBA Gene](/genes/gba1)
[APOE Gene](/genes/apoe)
[Personalized Treatment Plan for Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

References

[CYP2D6 genetic variants and levodopa response in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37158934/)

[CYP3A4 genetic polymorphism and MAO-B inhibitor response (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[MAPT H1 haplotype association with therapeutic response in PSP (2021)](https://pubmed.ncbi.nlm.nih.gov/33592689/)

[GBA variants in corticobasal syndrome and PSP: evidence for synucleinopathy overlap (2023)](https://pubmed.ncbi.nlm.nih.gov/36987234/)

[APOE genotype influences response to lipid-based therapies in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38456192/)

[Genomind Pharmacogenomic Testing](https://www.genomind.com)

[OneOme Pharmacogenomics Service](https://www.oneome.com)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Function](/hypothesis/h-d3a64f5c) — 0.42 · Target: DDC
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — 0.46 · Target: APOE
[APOE4-Selective Lipid Nanoemulsion Therapy](/hypothesis/h-c9c79e3e) — 0.61 · Target: APOE

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving pharmacogenomics-cbs-psp discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →